Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy

18 Feb 2025

Abstract excerpt

MET fusions (MET-F) are oncogenic drivers that remain poorly characterized. Analysis of 56 MET-F-positive tumors from an institutional cohort of 91,119 patients (79,864 DNA sequencing plus 11,255 RNA sequencing) uncovered two forms of MET-F pathobiology. The first group featured 5' partners with homodimerization domains fused in-frame with the MET tyrosine kinase domain, primarily originated from translocations,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Liver physiology and pathology
Share to Lung Cancer Treatments and Mutations
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39965191
DOI: 10.1158/2159-8290.cd-24-0417

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted TherapyPMID 39965191Read ↗

Molecular characterization of MET fusions from a large real-world Chinese population: A multicenter study.Semantic proximity Read ↗

MET fusions are targetable genomic variants in the treatment of advanced malignancies.Semantic proximity Read ↗

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profilingSemantic proximity Read ↗

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer.Semantic proximity Read ↗

MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.Semantic proximity Read ↗

Extensive MET alterations confer clinical response to MET inhibitors in gliomasSemantic proximity Read ↗

Targeting MET Dysregulation in CancerSemantic proximity Read ↗

Unveiling the Uncommon: Targeting Rare MET Fusions in NSCLC: A Comprehensive ReviewSemantic proximity Read ↗

The MET Oncogene Network of Interacting Cell Surface ProteinsSemantic proximity Read ↗

MET-dependent solid tumours - molecular diagnosis and targeted therapy.Semantic proximity Read ↗

Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET RearrangementsSemantic proximity Read ↗

High‐sensitive clinical diagnostic method for PTPRZ1‐MET and the characteristic protein structure contributing to ligand‐independent MET activationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.